Intellectual Property Rights and Vaccines.
Biotechnology
Commercialization
Infringement
Intellectual property
Legal
Patents
Vaccines
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
17
12
2021
pubmed:
18
12
2021
medline:
12
1
2022
Statut:
ppublish
Résumé
Over the past 20 years, there has been steady, year-on-year growth in the number of granted vaccine-related patents. It is therefore important that those involved in vaccine research should be aware of both the risks and opportunities that patents create. The aim of this chapter is to offer a brief introduction to how, and when, patent rights might become available to vaccine developers and to explain the potential risk of infringement of third-party patent rights and the potential consequences.This chapter begins with a brief introduction to the patent application process and the international patent systems. The advantages and drawbacks of patent protection are discussed, followed by an overview of patent infringement and the various legal safe-harbors that may be available for certain research activities. Other features of the patent system which may be of particular relevance in the vaccines context are also discussed, such as compulsory licensing, sovereign states' rights to use patented inventions and voluntary technology sharing agreements. The chapter concludes with a discussion of the SARS-CoV-2 (COVID-19) pandemic and recent developments in the field of vaccine patents that have arisen as part of the international response.
Identifiants
pubmed: 34918265
doi: 10.1007/978-1-0716-1892-9_28
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-518Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Jacob, R. COVID-19 and IP (2020) World Intellectual Property Review (published online 25 September 2020, last accessed 24 September 2021)
Chiron v Evans Medical [1997] EWHC 359
Biogen v Medeva [1996] UKHL 18
GSK v Wyeth [2016] EWHC 1045
Merck v Wyeth [2020] EWHC 2636
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (last accessed 24 September 2021)
https://www.who.int/initiatives/covid-19-technology-access-pool (last accessed 24 September 2021)
https://innovation.ox.ac.uk/technologies-available/technology-licensing/expedited-access-covid-19-related-ip/ (last accessed 24 September 2021)
https://investors.modernatx.com/news-releases/news-release-details/statement-moderna-intellectual-property-matters-during-covid-19 (last accessed 24 September 2021)
https://clinicaltrials.gov/ct2/show/NCT05001373 (last accessed 24 September 2021)